Inhibitory effect of exendin-4 on secretory group IIA phospholipase A2

Wonhwa Lee; Soyoung Kwak; Hyun Shik Lee; Dong Hee Na; You Mie Lee; Jong Sup Bae

doi:10.1016/j.bbrc.2015.02.165

Inhibitory effect of exendin-4 on secretory group IIA phospholipase A2

Wonhwa Lee, Soyoung Kwak, Hyun Shik Lee, Dong Hee Na, You Mie Lee, Jong Sup Bae

Kyungpook National University

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Exendin-4 (EX4), a glucagon-like peptide-1 receptor agonist, has been reported to attenuate myocardial ischemia and reperfusion injury and inflammatory or oxidative responses. The expression level of secretory group IIA phospholipase A2 (sPLA2-IIA) is elevated in inflammatory diseases. Lipopolysaccharide (LPS) upregulates the expression of sPLA2-IIA in human umbilical vein endothelial cells (HUVECs). Here, EX4 was examined for its effects on the expression and activity of sPLA2-IIA in HUVECs and mice. Pre-treatment of cells or mice with EX4 inhibited LPS-induced sPLA2-IIA expression and activity. Additionally, EX4 suppressed LPS-induced activation of cytosolic phospholipase A2 (cPLA2) and extracellular signal-regulated kinase (ERK) 1/2. Therefore, these results show that EX4 inhibited LPS-induced expression of sPLA2-IIA by suppressing cPLA2 and ERK 1/2.

Original language	English
Pages (from-to)	650-654
Number of pages	5
Journal	Biochemical and Biophysical Research Communications
Volume	459
Issue number	4
DOIs	https://doi.org/10.1016/j.bbrc.2015.02.165
State	Published - 17 Apr 2015

Keywords

Exendin-4 HUVEC sPLA2-IIA Inflammation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bbrc.2015.02.165

Cite this

@article{67cf1a94849848afb1d9a7c0185e0efc,

title = "Inhibitory effect of exendin-4 on secretory group IIA phospholipase A2",

abstract = "Exendin-4 (EX4), a glucagon-like peptide-1 receptor agonist, has been reported to attenuate myocardial ischemia and reperfusion injury and inflammatory or oxidative responses. The expression level of secretory group IIA phospholipase A2 (sPLA2-IIA) is elevated in inflammatory diseases. Lipopolysaccharide (LPS) upregulates the expression of sPLA2-IIA in human umbilical vein endothelial cells (HUVECs). Here, EX4 was examined for its effects on the expression and activity of sPLA2-IIA in HUVECs and mice. Pre-treatment of cells or mice with EX4 inhibited LPS-induced sPLA2-IIA expression and activity. Additionally, EX4 suppressed LPS-induced activation of cytosolic phospholipase A2 (cPLA2) and extracellular signal-regulated kinase (ERK) 1/2. Therefore, these results show that EX4 inhibited LPS-induced expression of sPLA2-IIA by suppressing cPLA2 and ERK 1/2.",

keywords = "Exendin-4 HUVEC sPLA2-IIA Inflammation",

author = "Wonhwa Lee and Soyoung Kwak and Lee, {Hyun Shik} and Na, {Dong Hee} and Lee, {You Mie} and Bae, {Jong Sup}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = apr,

day = "17",

doi = "10.1016/j.bbrc.2015.02.165",

language = "English",

volume = "459",

pages = "650--654",

journal = "Biochemical and Biophysical Research Communications",

issn = "0006-291X",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Inhibitory effect of exendin-4 on secretory group IIA phospholipase A2

AU - Lee, Wonhwa

AU - Kwak, Soyoung

AU - Lee, Hyun Shik

AU - Na, Dong Hee

AU - Lee, You Mie

AU - Bae, Jong Sup

PY - 2015/4/17

Y1 - 2015/4/17

N2 - Exendin-4 (EX4), a glucagon-like peptide-1 receptor agonist, has been reported to attenuate myocardial ischemia and reperfusion injury and inflammatory or oxidative responses. The expression level of secretory group IIA phospholipase A2 (sPLA2-IIA) is elevated in inflammatory diseases. Lipopolysaccharide (LPS) upregulates the expression of sPLA2-IIA in human umbilical vein endothelial cells (HUVECs). Here, EX4 was examined for its effects on the expression and activity of sPLA2-IIA in HUVECs and mice. Pre-treatment of cells or mice with EX4 inhibited LPS-induced sPLA2-IIA expression and activity. Additionally, EX4 suppressed LPS-induced activation of cytosolic phospholipase A2 (cPLA2) and extracellular signal-regulated kinase (ERK) 1/2. Therefore, these results show that EX4 inhibited LPS-induced expression of sPLA2-IIA by suppressing cPLA2 and ERK 1/2.

AB - Exendin-4 (EX4), a glucagon-like peptide-1 receptor agonist, has been reported to attenuate myocardial ischemia and reperfusion injury and inflammatory or oxidative responses. The expression level of secretory group IIA phospholipase A2 (sPLA2-IIA) is elevated in inflammatory diseases. Lipopolysaccharide (LPS) upregulates the expression of sPLA2-IIA in human umbilical vein endothelial cells (HUVECs). Here, EX4 was examined for its effects on the expression and activity of sPLA2-IIA in HUVECs and mice. Pre-treatment of cells or mice with EX4 inhibited LPS-induced sPLA2-IIA expression and activity. Additionally, EX4 suppressed LPS-induced activation of cytosolic phospholipase A2 (cPLA2) and extracellular signal-regulated kinase (ERK) 1/2. Therefore, these results show that EX4 inhibited LPS-induced expression of sPLA2-IIA by suppressing cPLA2 and ERK 1/2.

KW - Exendin-4 HUVEC sPLA2-IIA Inflammation

UR - http://www.scopus.com/inward/record.url?scp=84930738563&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2015.02.165

DO - 10.1016/j.bbrc.2015.02.165

M3 - Article

C2 - 25757907

AN - SCOPUS:84930738563

SN - 0006-291X

VL - 459

SP - 650

EP - 654

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

IS - 4

ER -

Inhibitory effect of exendin-4 on secretory group IIA phospholipase A2

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this